Hepatitis C virus in people who inject drugs (PWID): Regional Webinar

Watch Professor Graham Foster, Mr Duncan Hill, Dr Cyrus Abbasian and Dr Professor Rosmawati Mohamed in this expert discussion exploring Hepatitis C virus in PWID in Asia and Europe.

Despite significant treatment advancements, Hepatitis C virus (HCV) infection remains a worldwide health burden, particularly among people who inject drugs (PWID). Global prevalence of HCV in PWID is ~70% positioning this population as critical for treatment if we are to achieve the WHO elimination goal by 2030. This IOTOD webinar features Europe and Asia-based experts in HCV care and opioid dependence, to share best practices for addressing HCV in PWID, current care barriers and solutions to overcome them. By encouraging practice exchange between regions, we hope to learn lessons and together help optimise HCV care.

Agenda:

Opioid substitution therapy for PWID: a snapshot across Europe and Southeast Asia (01:26)
Psychosocial interventions for PWID (26:55)
HCV care among PWID: global and regional advancements (50:35)

Faculty

Cyrus Abbasian Addictions Psychiatrist, Nightingale Hospital, London, UK
Rosmawati Mohamed
Consultant Hepatologist, University Malaya Medical Centre, Kuala Lumpur, Malaysia
Graham Foster
Professor of Hepatology, Queen Mary’s University of London & Consultant, Bart’s Health NHS Trust, London, UK
Duncan Hill
Specialist Pharmacist in Substance Misuse, NHS Lanarkshire, Glasgow, Scotland

Sign-up to keep updated

This educational activity is currently undergoing review for CME-accreditation. Register your interest here to be informed following CME-accreditation approval and to stay abreast of upcoming IOTOD activities.
All your information will be kept secure. PCM Healthcare Ltd, a subsidiary of Cogora Group Ltd, may process your data for carefully considered purposes which are in our interests and enable us to enhance the services we provide. For further information, please see our privacy policy*.